A Randomized, Open-label, Single-center, Single-dose Study to Evaluate the Relative Bioavailability of a New Formulation Compared With the Approved Formulation of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) and to Assess Dose Linearity of the New Formulation in Healthy Subjects
Latest Information Update: 17 Dec 2023
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hypocalcaemia; Hypoparathyroidism; Hypothyroidism; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Takeda
Most Recent Events
- 20 Apr 2022 Status changed from recruiting to completed.
- 20 Dec 2021 Status changed from not yet recruiting to recruiting.
- 03 Dec 2021 New trial record